Sector

Healthcare

Healthcare continues to be a magnet for capital. The healthcare industry was amongst the most resilient during the pandemic. Global healthcare spending contracted slightly in 2020 but grew by approximately 6% up to $8.8 trillion in 2021. Companies will continue to benefit from high cash generation and attractive financing terms to roll out their growth plans.

Bryan, Garnier & Co's insights and news

Read the latest news, reports and newsletters from Europe’s Growth Investment Bank to find out more about current trends impacting investment banking activity and company performance.

Healthcare transactions

Bryan, Garnier & Co offers a complete range of investment banking services, from growth financing to mergers and acquisitions.

Bryan, Garnier & Co acts as Joint Bookrunner on Valneva’s Nasdaq and Euronext Paris EUR 102.9 million Follow-on Offering

Bryan, Garnier & Co acts as Sole Global Coordinator and Joint Bookrunner on Abivax’s EUR 49 million Cross-over Financing

Bryan, Garnier & Co acts as Sole Financial Advisor to Ganymed Robotics, a developer of computer vision software and robotics technologies for orthopedic surgeons, on its first €21 million closing of its oversubscribed Fundraising

Bryan, Garnier & Co acts as Sole Financial Advisor to Oncodesign on the sale of its CRO activities to Elyan Partners for €100m and the concomitant spin-off of its Biotech/AI activities

Bryan, Garnier & Co acts as Sole Global Coordinator & Sole Bookrunner on GeNeuro EUR 7.7 million Follow-On Offering

Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner on Aelis Farma’s Euronext Paris EUR 25m Initial Public Offering

Bryan, Garnier & Co acts as Sole Financial Advisor to clinical-stage biologics company BiosanaPharma on its global strategic partnership with Alvotech

Bryan, Garnier & Co acts as Sole Financial Advisor to MNH on the sale of AKLIA to Hoppen

Bryan, Garnier & Co is proud to act as Joint Bookrunner to Cell Impact on its SEK 349m Rights Issue

Bryan, Garnier & Co acts as Sole Financial Advisor to Wandercraft on its $45 million Fundraising

Bryan, Garnier & Co acted as Sole Financial Advisor to the shareholders of CMN on its partnership with MBO & Co

Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner to Nicox on its EUR 15 million Follow-on Offering of shares and warrants

Bryan, Garnier & Co acts as Lead Joint Bookrunner to leading German Specialty Pharmaceuticals provider Medios AG on its EUR 93 million Follow-on Offering

Bryan, Garnier & Co acts as Sole Global Coordinator and Joint Bookrunner on Enapter Follow-On Offering of EUR 30m

Bryan, Garnier & Co acts as Joint Bookrunner on Valneva’s Nasdaq & Euronext Paris USD 102m Follow-on Offering

Bryan, Garnier & Co acts as Sole Financial Advisor to XVIVO on its acquisition of STAR Teams, and as Joint Global Coordinator on subsequent SEK 250 million Follow-on Offering

Sector

Healthcare

Bryan, Garnier & Co's insights and news

European cannabis

Bryan, Garnier & Co becomes a partner in the Euronext Tech Leaders initiative

The future of cybersecurity: TempoCap and Bryan Garnier lead the discussion on market trends and business concerns in 2023

Digital Assets Service Providers: A new era for capital markets

KOL call: Idefirix for Kidney Transplantation

Bryan, Garnier & Co Expands Software and Fintech Investment Banking team with new Managing Director Jean-Malo Dupart

Cell therapy Innovation: CAR T

Hidden value in consumer healthcare

Opportunities in the fast-growing EV charging market